SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " tom " 28,313 found 🔀 AI-powered Shuffle
The Odds: The Economy
Volkswagen reportedly planning to axe 100,000 jobs
Volkswagen, one of the world’s largest automakers, is reportedly planning to axe as many as 100,000 jobs over the next few years, representing 15% of its global workforce.
PlayStation encourages Blu-ray adoption by deleting purchased movies from customer accounts
PlayStation encourages Blu-ray adoption by deleting purchased movies from customer accounts
Why Pollinators Matter for Human Health | Johns Hopkins Bloomberg School of Public Health
New research shows that wild insect pollinators play a critical role in nutrition and livelihoods.
Trump forced to drain the reflecting pool swamp
Jonathan Freedland speaks to Arwa Mahdawi about why this project is proving to be such an embarrassing failure for the president
Cascades doubles down on business case for sustainability
The fiber specialist laid its path forward in a 2026-2030 sustainability plan. It’s emphasizing supplier vetting and its capacity to assist customers with their sustainability goals as it continues to strive for widely recyclable packaging.
Karl Stefanovic Speaks Out on Nine Exit After Tommy Robinson Scandal
The 'Today' host declares himself 'free' in a YouTube statement after Nine ends his contract following a deleted Tommy Robinson podcast episode.
Gemini begins rolling out for existing Android Automotive vehicles
Some months after its confirmation, Gemini for Android Automotive appears to be finally rolling out to existing vehicles.
I own a Turkish restaurant in SF. The World Cup changed my business.
Turkey playing in San Francisco as part of the FIFA World Cup 2026 has brought new customers to one restaurant, Turquaz's owner told Business Insider.
Alito’s testy reaction to Sotomayor underscores tensions at Supreme Court
When major rulings are announced, most Supreme Court justices practice a kind of studied impassivity. Then, there’s Samuel Alito.
NTT DATA | Transforming Data Into Exceptional Fan Experience
We worked with Penske Automotive Group to create a mobile application to amplify the fan experience and make the iconic Indianapolis Motor Speedway a smart venue through NTT Smart Solutions.
Slate's $24,950 EV truck is tiny and ridiculously customizable
Slate's pickup truck just revealed its sub-$25k price. So we tested out its build-your-own tool to see how the accessories work.
NHL Mock Draft: Flyers Projected to Make Massive Choice... Literally
X Games brings top action sports athletes to town in Sacramento debut
Clippers draft pick Narcisse Ngoy announces he will play at Auburn next year in unique draft-and-stash situation
World Cup 2026: USMNT stunned by Türkiye in stoppage time, losing perfect group stage run
Rep. Moulton downplays panic over Dem socialists: “lot of things we’re united on”
TravelTech Show, Business Travel Show Europe name 2026 innovation award winners
Arcube, ImpersonAlly, Acai and Nowadays were recognized in separate competitions for travel technology innovations spanning airline retailing, brand protection, contact center automation and meetings management.
Rep. Moulton urges Supreme Court reform after ruling expands Trump’s immigration power
Children's Minnesota doctor warns of Benadryl challenge dangers
Senate Indian Affairs Committee Advances Mark Cruz’s Nomination to Lead Indian Health Service
U.S. Senator Lisa Murkowski (R-Alaska), Chair of the Senate Committee on Indian Affairs, led a nomination hearing to consider Mr. Mark Cruz, of Oregon, to be Director of the Indian Health Service within the U.S. Department of Health and Human Services and expressed her intent to support his nomination. Representative Tom Cole (R-Okla.), a citizen […]
The Business of Beauty Global Forum: Beauty’s New Future
Tom Hale, Violette Serrat, Dr. Fatima Cody Stanford and more explored what the future of beauty will look like, and who will shape it, in the final session of The Business of Beauty Global Forum 2026.
Three years of construction frustrates Marcellus businesses, residents
El Paso business expands cooling steps as triple-digit heat persists
USA vs. Türkiye score, live updates: USMNT finishes group play before knockout match with Bosnia and Herzegovina
Plan Intl: ‘Mental health impact of Venezuelan quakes can last for years’
World Cup 2026: Christian Pulisic won't start for USMNT's group stage finale against Türkiye
Groundbreaking held for new youth mental health treatment facility in Saco
Health concerns still loom after LAFD knocks down Boyle Heights warehouse fire
As San Joaquin County sees rise in rabid bats, public health says not to worry
How the LaMelo Ball era in Charlotte came to its sudden end
Senators demand probe into reports of secret Trump-Emrati crypto deal: ‘let them say it under oath’
Video of Tom Sandoval pushing ex's dad into firepit surfaces
Bravo alum Tom Sandoval is in the midst of another controversy after video surfaced showing an altercation with his ex and her father.
Liberty injury report: Star forward Satou Sabally in concussion protocol
What science tells us about the health risks of Roundup
What science tells us about the health risks of Roundup
Sports with Sam: FIFA Fan Fest kicks off at Olympic Park: U.S. vs.Turkey
Nonprofit aims to help displaced workers as businesses adopt artificial intelligence
MLB All-Star 2026: Shohei Ohtani and Ernie Clement receive automatic spots after winning Phase 1 of fan vote
Health Watch: Scientists say animal therapy helps critically ill patients, prompting new legislation
30 is the new 35: How Ormond Beach businesses are urging drivers to slow down
Making Our Own Luck
We are cross-posting a piece that former NIH official Kris Willis wrote for Macroscience. Kris is now the President and Founder of the Woodley Park Institute, for which I’m a board member. Picking winners or hedging bets? Federal science agencies have long wrestled with the question of how to ensure their billions of dollars of grants and contracts result in maximum benefits for Americans. On the surface, it might seem that a goal-oriented, interventionist style of management would be the best policy: prioritize our most pressing problems and distribute funding accordingly.This top-down strategy creates a unique hazard, though: bad choices can send resources in the wrong direction, resulting in slow progress that impedes the delivery of tangible benefits to citizens. Moreover, if decision makers pursue an applied advance when the underlying scientific principles remain poorly understood, they risk costly failures and a loss of support for the research enterprise at large. Examples include Nixon’s 1971 War on Cancer, undertaken on the premise that a cure could be achieved in less than a decade, the drive to build an operational commercial fusion plant by the mid-1990s, and the National Plan to Address Alzheimer’s Disease, which failed to produce the effective treatments and prevention strategies promised by 2025. The contrasting laissez-faire approach is to hedge your bets. If the path to an advance is impossible to predict, then the wisest choice might be to distribute funding to as widely as possible. The main risk of this strategy is that spreading funding thinly may limit the resources available to the most promising research, resulting in the same negative outcomes as the interventionist approach: limited support for the most promising topics, slow progress, and delayed returns. In reality, at science agencies like the National Science Foundation and National Institutes of Health, program managers navigate between these two extremes, setting some funds aside to target high-priority areas and using the rest to cover the widest possible range of meritorious proposals. This middle path seems like the most rational way to proceed, but it still requires making choices. How much should be set aside for high priority topics? What should those topics be? How should we define merit? Expert opinion can provide a helpful guide, but leading experts can have remarkably different opinions about what matters and what should be prioritized. Moreover, experts and administrators alike can be risk averse, giving an edge to high-profile, well-established concepts. What’s really needed is a data-driven framework to help guide decision-making, one that doesn’t simply repackage prestige or incumbency. Recognizing breakthroughs years in advance Many breakthroughs fail to attract funding or recognition at the earliest stages of development. Katalin Karikó, for example, spent years struggling to win grants for work on mRNA that would eventually win her and Drew Weissman a Nobel Prize. Similar stories can be told about Jim Allison’s groundbreaking studies leading to the development of cancer immunotherapy, Stan Pruisner’s demonstration that prions can self-replicate without DNA, or Robin Warren and Barry Marshall’s proof that Helicobacter pylori, not stress, causes ulcers. Yet at some point, the scientific community recognizes and responds to transformative breakthroughs like these. How does that change happen? And what if science funders could identify the areas that are on the cusp of a breakthrough? Those questions led my collaborators and me to study how scientists responded to past breakthroughs. Based on patterns in that data, we developed a means of predicting future breakthroughs, using biomedicine as a proof of concept. It’s worth taking a moment to describe how our approach works. Briefly, our prediction process begins by grouping the 18 million or so peer-reviewed papers in PubMed, the authoritative database of biomedical research, into roughly 50,000 unique topics. A small subset of these topics are so widely acclaimed as breakthroughs that they have been recognized with a major prize like a Nobel or a Lasker Award. We theorized that studying the development of these outliers over time, especially before they gained acclaim, was the key to identifying future instances of them. After defining topics, we chose 21 representative breakthroughs and asked what they looked like before they won prestigious prizes. To answer that question, we re-ran our topic-mapping algorithm repeatedly, winding back the clock one year each time, stringing together the years to follow the progress of each field as it grew and advanced. We found that in each case, the years leading up to a discovery followed a pattern: a burst of papers on a new, rapidly evolving topic, many of which quickly became influential. These characteristics—the percent of papers that are new, the percentage of papers that are brought in from other topics, and the influence of each individual paper—can all be measured separately for any given topic. Together, they act as a predictive signal that is detectable an average of five years before a transformative discovery is made, and up to thirty years before the discovery receives a major prize. Scanning the current research landscape for topics that display this signal allows us to predict what work will likely produce a future breakthrough. Each year we analyzed includes four or five signals, a number that appears to have remained constant across a twenty year time frame. In their classic work on the sociology of science, Bruno Latour and Steve Woolgar established that the desire to participate in a major discovery is an important motivator for scientists as they consider whether they should take up (or abandon) a research problem. Although further work is needed, the simplest explanation for our results is that this behavior is widespread enough to detect at scale. A foundational advance, or something like it, draws the attention of scientists and causes them to change the direction of their research. They vote with their feet, staking their own reputation and careers by publishing on and citing the new idea. That upswell of interest is the foundation of our breakthrough signal. What kind of research does our model identify as a breakthrough? After building a model based on the patterns in our 21 preselected breakthroughs, we tested it by identifying all early signals of discovery from 1994 through 1997. Of the 18 signals we found in that time period, 17 can be traced forward in time to a breakthrough. Examples include super-resolution fluorescence microscopy (see the image above), the directed evolution of proteins and enzymes (Chemistry Nobel, 2018), and sequencing the human genome (National Medal of Science, 2008). The discovery of the role of leptin signaling in obesity is a particularly interesting case study. Around 1950, scientists noticed the existence of a type of lab mouse that suffered from a unique inherited form of obesity. When given the freedom to choose their own diet, these mice ate more than normal and preferred food that was high in fat. Researchers had few clues as to why the animals overate; early experiments pointed to the existence of a soluble ob factor found circulating in the bloodstream that regulated appetite, but its identity was unknown. In 1994, Jeffrey Friedman and colleagues identified and sequenced the ob gene, noting that the protein it encoded appeared to fit the profile of a circulating factor. A year later, a trio of high-profile publications demonstrated that ob was a hormone that regulated body weight and fat deposition by regulating appetite. One of these was co-authored by Friedman, who christened it leptin from the ancient Greek word for thin. Using our model, the data from 1996 make it clear this advance would become a breakthrough. Scientists had flocked to study the biology of the new hormone, generating the flurry of new papers and citations required to produce a signal. One of these demonstrated that serum leptin concentrations reflected the amount of adipose tissue in the human body, providing clinical validation of the earlier mouse studies. Before the identification of leptin, scientists were unable to point to a specific molecule that controlled appetite and adiposity, so that it was impossible to rule out non-physiological causes of obesity; its characterization fundamentally changed our concept of weight gain. In 2010, Friedman and fellow pioneer Douglas Coleman were awarded a Lasker for the discovery. Our work also identifies breakthroughs in clinical practice and behavioral and social sciences, even though these areas are less likely to draw the attention of major prize committees. One example that falls into this category is the introduction of endovascular aneurysm repair, a minimally invasive surgical procedure for the treatment of abdominal aortic aneurysm, a leading cause of death among Americans over the age of 65. Relative to the previous standard of care, it reduces in-hospital mortality by almost four-fold. In 2017, Timothy Chuter received the American College of Surgeons’ prestigious Jacobsen Innovation award for his multiple refinements to the technique. Another under-recognized breakthrough identified by our model is the development of standardized survey instruments to assess the quality of life for HIV+ patients. The antiretroviral cocktails introduced in the mid-1990s reduced AIDS mortality, but treatment came with serious side effects. The new evaluations showed that patients whose disease progressed had worse physical functioning than Americans with other chronic diseases, while those who were asymptomatic maintained a health-related quality of life on par with the overall US population. This evidence made it possible for patients and activists to argue that even in the absence of a total cure, and in spite of the side effects, alleviation of symptoms was a worthwhile priority for clinicians. My colleagues and I have failed to identify any significant recognition for the physicians and health policy experts who pioneered this advance, although in 2016, researchers called for the World Health Organization to set targets for good health-related quality of life as part of its framework to end the AIDS pandemic. From forecasting to funding How should science funders use our predictions? Any serious discussion of what we should do with this new capability needs to begin with an understanding of its limitations. We can’t (and shouldn’t) invest all of our resources in the small number of topics predicted to produce breakthroughs. Innovative new fields are born from existing ones; they rarely arise de novo. If funders don’t maintain a diverse portfolio, the breakthroughs of tomorrow will have no antecedents. Think of this as eating the seed corn, or killing the goose that lays the golden egg. There are also multiple goals of funding beyond basic scientific discovery, including translating discoveries into clinical practice, developing new technologies, supporting economic development, and training new scientists. The investments needed to accomplish these goals are likely different from those required to support emerging breakthroughs. Finally, we must be aware that we may not capture every instance of a breakthrough. The concept is fuzzy, and not every significant discovery is recognized with a major award. Further, breakthroughs are rare, meaning that our dataset is, by necessity, small. This makes formal estimates of accuracy challenging. Although our overall success rate appears to be high, any one signal may turn out to be a false positive. We found one apparent example: the development of the third generation COX-2 inhibitors, Vioxx and Celebrex, which were much celebrated in the early 2000s as effective but non-addictive pain relievers, meets all the algorithmic criteria of a breakthrough. Five years after it received FDA approval, researchers demonstrated that Vioxx was associated with serious cardiovascular complications, and the manufacturer voluntarily pulled the drug from the market. Celebrex remains available, although like other NSAIDs, it carries an FDA warning for increased cardiovascular risk. Decision makers who were overly focused on the breakthrough potential of this research might have wasted substantial resources nurturing an area that ultimately proved to be a failure—but so would those who relied on expert opinion at the time. That said, the potential benefits of funding the next mRNA vaccine or cancer immunotherapy years earlier than we might have are large. When we can’t assume the outcome of an action, it’s worth conducting an experiment. Can targeted support for areas that are poised to produce a breakthrough increase the return on scientific investment without cannibalizing future advances? With the necessary administrative infrastructure in place, conducting this experiment would be straightforward. First, identify all the breakthrough signals between 2018 and 2023, select half at random, and commit to a decade of investment. For biomedicine, a six year window should yield about 30 topics with the potential to produce a breakthrough. Providing strong support to half of these might be accomplished for $300 million a year. That’s roughly half of the recent annual budget of the NIH Common Fund or around 20% of the fiscal year 2025 budget for ARPA-H. After five years, then again at ten, compare to see which group — the one that was actively managed, or the control — produced more breakthroughs, and on what timescale. Although we used biomedicine as an example, the same experiment could just as well be run for physics, materials science, or any other discipline. Any attempt to undertake such an experiment should keep three points top of mind. First, we can predict the topic of future breakthroughs, but the people and vision for how to move the work forward are still important. In practice, this means success requires active program managers with the expertise to develop the science and the authority to do so, including by recruiting investigators. Second, we would be wise to learn from the failures of past attempts to fund transformative research. High among these are funding modestly repackaged work, confusing the genuinely novel with the merely unfamiliar, and relying too much on incumbent investigators. All of these risks can be mitigated by thoroughly and intelligently integrating high quality data into portfolio management. Finally, we need to have patience. Even with strong funding support, producing a breakthrough takes time. If supporting breakthroughs is the best way to nurture the birth of new fields, we also need to accurately describe and properly manage the other two stages, so that we invest wisely throughout the productive lifetime of ideas and divest once they reach the point of diminishing returns. We would benefit from more study of all of these phases, especially the transition from one to another. More research could answer questions like: When does a breakthrough become an established field? How do the availability of funding, the size and characteristics of the available workforce, and the accumulation of evidence that disagrees with prevailing models affect a field’s decline? Exactly how do old ideas give birth to new ones, and can we speed up the process? The more we understand about the dynamics of scientific progress, the better we can maximize the odds that our curiosity leads to results. I’d call that finding a way to make our own luck.
World Cup 2026 free livestream info: How to watch every match
Judge halts Trump executive order aimed at mail voting in states that challenged it
Rays' Craig Kimbrel allows 1-out, 9th-inning homer to spoil combined no-hitter against Royals
Edgefield County health fair offering free screenings, vendors, and entertainment
JOHNSTON, S.C. (WJBF) — A free community health fair is headed to Edgefield County. “Prevention Today for a Healthier Tomorrow,” set for Friday, June 26 from 10 to 1 at Strom Thurmond High School i…
Original 'Drag Race' star reportedly hospitalized in critical condition after fatal car crash
'RuPaul's Drag Race' season 1 queen David 'Jade' Sotomayor reportedly hospitalized after a fatal car crash in Chicago, with Monica Beverly Hillz telling EW she wants fans to send the family 'good vibes.'
Bio-Techne, a Minneapolis life sciences firm with 500,000 products, to be sold to German company for $11.3 billion
Renewed Dansby Swanson makes Cubs history with 15 RBI across 3 games vs. Mets, including 11 in doubleheader
World Cup schedule, live updates: Germany, Japan and USA return as Matchday 3 continues
LaMelo Ball raises more questions than he answers in Minnesota
Gov. Shapiro on Mamdani-backed wins in NYC: Candidates doing ‘performative politics’ must learn ‘how to deliver results’
Fed Rule Effectively Puts Automaker Polestar Out Of Business In The U.S.
Volvo’s upscale electrified division pulls the proverbial plug on future U.S. sales because of its ties to China.
World Cup schedule, live updates: USA, Group D returns Thursday as Matchday 3 continues
Butte County approves Gridley behavioral health center with $7M contract
Cheshire orchard closes after 75 years in business
A longtime Cheshire orchard has announced its closing for good. In a message shared with customers, the family that owns Drazen Orchards said it is now permanently closed and will not reopen for the foreseeable future. The orchard has been open since 1951. The Drazen family said the decision was difficult, citing rising operating costs, the physical demands of running…
LaMelo Ball trade grades: The Hornets' logic makes sense, but what is Minnesota's thought process?
WATCH LIVE: Mullin testifies before House committee on DHS oversight
Aurora program breaks down barriers to one of the most expensive youth sports
Health systems must shift AI use from automation to transformation
While healthcare investments in AI are two to three times that of other industries, most providers focus AI's power on tackling administrative tasks. But AI's true value is in transforming care, explain experts at the HIMSS AI in Healthcare Forum.
NFL offseason power rankings: No. 30 Arizona Cardinals restart the road to relevance, yet again
Penguins Named Best Landing Spot For Hurricanes UFA Goalie
Mets commit six infield errors in embarrassing loss to Cubs: 'This team is in the depths of despair'
Regenerative Agriculture and Population Health
Regenerative agriculture can enhance food quality and reduce harmful exposures through improved soil biology, biodiversity, and ecosystem health, yielding downstream benefits for agriculture, food systems, and human health. It may improve profitability through greater land resilience and lower input costs and may deliver benefits to farms, farmers, communities, and the broader environment. More research is warranted to understand the full range of potential health benefits of regenerative agriculture.
How should European scientists respond to the US AI kill switch?
Earlier in June, Europe’s worst fears of technological dependence were confirmed when the White House ordered the AI firm Anthropic to stop non-US citizens using its leading models. This kill-switch moment crystalised anxieties in Brussels that the continent, lagging the US on the creation of leading-edge AI models, is now a technological of vassal of Washington. The shock has specific implications for European scientists and universities. Some governments are now worried that with AI being integrated into labs, Donald Trump now has his finger hovering over an off switch for European science. “Having restrictions on this tool, it can have an impact on our own research,” said France’s research minister, Philippe Baptiste, at the VivaTech conference in Paris on June 18.Baptiste, himself a former academic, said that colleagues in mathematics had recently warned him they were now cut off from leading-edge US models, risking their work. “This model is not available anymore now because of the US restriction, and for the first time this had an impact on mathematics,” a field where large language models (LLMs) are making a significant contribution, said Baptiste. So, should European scientists avoid relying on US models in the future? Or would this be a self-harming overreaction? And how is AI being used in science, anyway? What happened?On June 12, it emerged that Washington, citing cybersecurity concerns, had ordered Anthropic to stop non-US citizens using two models: Claude Mythos 5, and Claude Fable 5, a version of Mythos but with guardrails to prevent abuse. Anthropic said Washington’s concerns were overblown. But forced to follow the order, yet with no way to check who was using the models, the company suddenly shut down access for everyone, US citizens included. There’s still no agreement on how to restore broad access. But last week, Bloomberg reported that select US companies, and the US government, still had access to Mythos despite the ban, but the EU’s cybersecurity agency Enisa had been shut out. Class division of researchersIn the longer term, access outside the US should be restored, said Marcel Salathé, co-director of the AI centre at the Federal Polytechnic School of Lausanne (EPFL), because a permanent restriction would be financially ruinous to US AI firms. “Even Trump will eventually budge to economic pressure,” he said.However, US AI firms might end up operating rather like banks, doing due diligence on users of their leading-edge AI models, he went on.European scientists are unlikely to fall foul of such checks, he said. But having a Chinese postgraduate in their lab, or doing a type of research the US disapproved of, could potentially result in access being denied. “It will create a sort of class division of researchers,” he said. More than frontier modelsHowever, successfully deploying AI in science is about far more than just having access to leading LLMs such as Mythos.Instead, many science-specific tools, most famously Alphafold, which predicts protein folding structures, require “far less” computing power to train than frontier models, well within the capabilities of European supercomputers, according to a recent analysis by the Arq Foundation, a Brussel-based AI think tank. Instead, tools such as Alphafold are possible because certain fields, like protein folding, weather prediction or astronomy, have large, clean, standardised datasets that can be used to train predictive models. Rather than compute, “data is the central constraint for AI for science,” the report says. For example, a less powerful physics model trained on CERN’s data “will be more valuable than the best model without certain data,” said Bengüsu Özcan, author of the report. European advantage?Europe could therefore steal a march by using its scientific data and infrastructure to create models US digital giants cannot. “They might actually match or go even beyond what these big [US] companies are doing,” said Özcan.Indeed, some European start-ups hope to create automated testing labs to create the kind of standardised data that could speed up the discovery of new materials. Materials scientists say there’s currently too little data to train models. AI scientistsHowever, even if the bottleneck for AI in science is often data, rather than compute, being at the mercy of the US for LLM access could still become a problem for European scientists. A new class of “AI scientists” based on leading LLMs is also emerging, Özcan’s report says.Unlike domain-specific tools like Alphafold, these try to automate day-to-day scientific work, by providing an overarching tool that coordinates specific models to synthesise existing literature, generate hypotheses or run analysis of data. The problem for Europe, however, is that these tools are sometimes based on US leading models. Google Deepmind’s AI Co-Scientist, for example, is built on Google’s Gemini LLM. Systematic failureThese scientific automation tools are still in their early stages, and still exhibit “systematic failures on scientific tasks,” Özcan’s report says. One of the problems is that the messy, day-to-day process of scientific discovery is largely not documented, meaning LLMs don’t have a good source of data to learn how scientists actually work. Meanwhile, some tasks, such as literature synthesis, don’t typically require access to leading edge models.However, the performance of AI scientific assistants could improve as companies such as Google pour resources into developing them. Rely on US“Unfortunately, for scientific assistants, there is not much we can do right now except rely on US frontier AI,” said Antoine Bosselut, a natural language processing expert based at EPFL. Chinese-built open models, which can run on local computers, lessening the risk of a shutdown, are touted as one alternative to US dependence. There’s also Mistral, once seen as Europe’s main AI hope, but the Paris-based company has seen its recent models fall behind in performance. But the Chinese alternatives are generally not as capable as US frontier AI models, said Bosselut, unless paired with fiddly, custom tools that allows them to act as independent agents. “Most scientists do not have the time,” he said. Don’t jump ship yetAlthough the kill switch moment is seen a warning shot for European scientists, it doesn’t mean labs should abandon US AI tools immediately. “I do not think the right response is simply to abandon US-based models and systems under the banner of sovereignty or independence,” said Mattias Björnmalm, secretary general of the Cesaer university association. “That would be an overreaction.”Related articlesEuropean sovereignty in AI requires ‘ugly trade-offs,’ say experts Robotic lab start-up makes case for €500M EU-funded materials testing facilityAI in science: is it useful? Instead, European researchers need to ask themselves whether they’re becoming dependent on technology that could be turned off in Washington, said Özcan. “They might not see this today, but they should really start asking this question,” she said. European researchers need a plan B, said Salathé. “I would recommend to every researcher, very proactively explore alternatives.”Own toolsIn addition, Björnmalm and others want European research institutions to develop their own scientific AI tools.Instead of signing AI deals with US digital giants, European universities should be using this money to create their own models, which may end up being superior for research, said Sabine Leonelli, an expert on the use of AI in science at the Technical University of Munich. “Universities in Europe seem to be happy to sign commercial contracts with US companies on the assumption [their AI tools] are better,” she said. But US frontier LLMs are typically opaque, and have been developed without independent scientific input, she said. “This is not good enough for science.”Last year, Swiss researchers released Apertus, an LLM designed to be completely transparent, from its development methods to its training data. The idea is that this makes scientific tools built on top of the model far more reproducible than with closed, commercial alternatives.“Europe needs more of this: serious capacity-building that gives researchers, universities and companies credible options,” said Björnmalm.
Kustom Entertainment Announces $5.5 Million Divestiture of Legacy Video Solutions Division to Cycurion, Advancing Live Entertainment Focus
Kustom Entertainment announces divestiture of video solutions division to Cycurion, enhancing focus on live events and ticketing.Quiver AI SummaryKustom Entertainment, Inc. announced a binding agreement to sell its legacy video solutions division to Cycurion, Inc., in a deal worth up to $5.5 million, including $1.25 million in cash and a $4.25 million promissory note. The transaction, expected to close in July 2026, will provide Kustom with finan
KUSTOM ENTERTAINMENT, INC. ANNOUNCES BINDING AGREEMENT FOR THE DIVESTITURE OF ITS VIDEO SOLUTIONS SEGMENT TO FULLY COMPLETE LIVE ENTERTAINMENT PIVOT
Transaction Structured to Provide Up to $5.5 Million plus 2,000,000 Warrants to acquire shares of common stock of Cycurion, Inc.; Follows Previously Announced Major Live Music Expansion Partnership with Gilley’s Park City OVERLAND PARK, KS, June 25, 2026 (GLOBE NEWSWIRE) -- Kustom Entertainment, Inc. (Nasdaq: KUST) (the “Company”), a live entertainment and music festival company, today announced it has entered into a binding agreement for the divestiture of its legacy video solutions division to
KUSTOM ENTERTAINMENT, INC. ANNOUNCES BINDING AGREEMENT FOR THE DIVESTITURE OF ITS VIDEO SOLUTIONS SEGMENT TO FULLY COMPLETE LIVE ENTERTAINMENT PIVOT
Transaction Structured to Provide Up to $5.5 Million plus 2,000,000 Warrants to acquire shares of common stock of Cycurion, Inc.; Follows Previously...
New entertainment zone allows alcohol to-go
John Morgan reveals the name of his new Florida political party
Business - Maritime traffic picks up in Strait of Hormuz, but uncertainty lingers
Cubs to acquire pitcher David Peterson from Mets for prospect
Shohei Ohtani calls his own pitches vs. Twins after apparent dispute with catcher Dalton Rushing
LaMelo Ball trade rumors: Ranking best fits for Hornets star guard
Mookie Betts continues resurgent streak with 300th career homer in Dodgers win
Hollywood production house closes, citing entertainment industry struggles
Hollywood production house closes, citing entertainment industry struggles
Elk River brewery owner says future of business depends on whether city approves data center next door
NBA Draft Round 2 winners and losers: LaMelo Ball on the move? Must the Celtics trade Jaylen Brown? And players were drafted as well?
Congressman: ‘Trump clearly decided that his crisis was more important than America’s crisis’
Caesars Entertainment announces online gambling partnership with Wabanaki nations
Sen. Elizabeth Warren: ‘Thank you Donald Trump’ for the issue that will decide the midterms
Sen. Van Hollen: Trump is saying he ‘doesn’t give a damn’ about people who can’t afford housing
Restaurants Care Resilience Fund helps local businesses stay afloat
2026 NBA Draft grades, second-round pick-by-pick analysis
Cardona family business named rookie of the year, yet family still blocked from E-2 visa
NBA Draft: Knicks continue spate of trades, deal No. 31 and 55 picks to Rockets after moving out of first round
DolCas Biotech: CEO highlights Morikol marine collagen science and delivery format R&D
Porsche unveils the new 911 GT4 R for global customer motorsport
For the first time, a car designed for global GT4 racing is based on the 911 platform.